Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
Hospitalizations from COVID-19 continue in the United Kingdom with more than 235,000 admitted year-to-date and with ~5,000 currently hospitalized.1 In addition, Humanigen believes that treatment with lenzilumab may deliver economic value to the healthcare system.
- Hospitalizations from COVID-19 continue in the United Kingdom with more than 235,000 admitted year-to-date and with ~5,000 currently hospitalized.1 In addition, Humanigen believes that treatment with lenzilumab may deliver economic value to the healthcare system.
- Lenzilumab binds to and neutralizes GM-CSF, potentially improving outcomes for patients hospitalized with COVID-19.
- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
- https://doi.org/10.2147/CEOR.S360741
Humaneered is a trademark of Humanigen, Inc.
Yescarta and Tecartus are trademarks of Gilead Sciences, Inc., or its related companies.